
The S&P/ASX 200 Index (ASX: XJO) is having a poor end to the week. In afternoon trade, the benchmark index is down 0.5% to 8,480.5 points.
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:
The 4DMedical share price is up 3% to $6.47. This morning, the respiratory imaging technology company revealed that its CT:VQ product has received CE Mark certification for commercial use in the European Union. The company notes that this allows it to immediately commence commercial engagement with healthcare providers, which sets up a pathway for clinical adoption and collaboration with major European hospital networks. 4DMedical's CEO and founder, Andreas Fouras, said: "CE Mark certification for CT:VQ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets. Combined with FDA clearance, 4DMedical now holds regulatory approval to rapidly commercialise CT:VQ across both the U.S. and the EU."
The Clinuvel Pharmaceuticals share price is up 1.5% to $9.93. This has been driven by news that the biopharmaceutical company is showcasing at America's largest dermatology conference. Clinuvel's head of North American operations, Dr Linda Teng, said: "Following the success of the 2025 AAD Meeting, our team has refined its approach to ensure maximum engagement with the dermatology community ultimately aimed at helping to treat patients with melanocortin therapies. We know there is great demand from physicians who wish to offer more to their vitiligo patients, while interest in our commercial program for EPP continues to grow as patients seek approved therapy."
The Life360 share price is up 1.5% to $19.28. This week, Bell Potter put a buy rating and $37.75 price target on its shares. This is almost double its current share price. Commenting on its expectations for the first quarter, the broker said: "After setting expectations relatively low for Q1, there is some chance of a small beat, perhaps more in the adjusted EBITDA margin rather than MAU growth."
The Silex Systems share price is up 1% to $5.34. This morning, the laser uranium enrichment technology company advised that Global Laser Enrichment (GLE) has received preliminary approval for a major US government funding package. GLE is the exclusive licensee of the Silex uranium enrichment technology. The performance-based incentives package will provide up to US$98.9 million (A$142.6 million) in tax and other economic incentives.
The post Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026